HiFiBiO SAS
HiFiBiO SAS, a leading biotechnology company headquartered in France, is at the forefront of innovative solutions in the field of immunotherapy and drug development. Founded in 2015, the company has rapidly established itself as a key player in the biopharmaceutical industry, with a strong operational presence across Europe and North America. Specialising in the development of advanced monoclonal antibodies and immune profiling technologies, HiFiBiO SAS offers unique products that enhance the understanding of immune responses in various diseases. Their proprietary platforms enable precise characterisation of immune cells, setting them apart in a competitive market. With a commitment to advancing personalised medicine, HiFiBiO SAS has achieved significant milestones, including strategic partnerships and collaborations that bolster its market position. The company continues to drive innovation, contributing to the evolving landscape of therapeutic solutions.
DitchCarbon Score
How does HiFiBiO SAS's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
HiFiBiO SAS's score of 26 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
HiFiBiO SAS's reported carbon emissions
HiFiBiO SAS, headquartered in France, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that HiFiBiO SAS may still be in the early stages of developing its climate strategy or reporting framework. As the company operates within the biotechnology sector, it is essential for HiFiBiO SAS to consider establishing measurable climate commitments and reduction targets in line with industry standards. This could include aligning with frameworks such as the Science Based Targets initiative (SBTi) to enhance transparency and accountability in their environmental impact. In summary, while HiFiBiO SAS has not yet disclosed any emissions data or climate commitments, there is an opportunity for the company to develop a robust sustainability strategy that addresses carbon emissions and contributes to global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
HiFiBiO SAS is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
